NEEDHAM, Mass.--(BUSINESS WIRE)--BostonSight, an international leader in the treatment of patients with complex corneal disease, today announced that its CFO, Sara Yost, will be promoted to CEO effective March 11, 2019. She will replace current President and CEO Gene Guselli, who is retiring. Guselli will assist with the transition and remain with BostonSight as an Advisor through the end of 2019.
Gene Guselli joined BostonSight as President and CEO in April 2016. With over 30 years of experience pioneering innovations in healthcare, Gene lead the successful launch of BostonSight SCLERAL, helping to deliver unparalleled scleral lens design for doctors and patients.
Sara Yost has been with BostonSight since 2002, holding several positions in administration, finance and operations, including the past three years as CFO. Yost has a BS in Health Management and Policy from the University of New Hampshire and earned an MBA, High Distinction, Accounting from Bentley University. As CEO, she will be focused on expanding the availability of BostonSight’s PROSE and SCLERAL products, with a near-term emphasis on international expansion.
“Sara’s unparalleled knowledge of the BostonSight organization and industry, coupled with the deep relationships she has formed with its employees and network partners made Sara the ideal choice to succeed Gene as CEO,” said David Rosenbloom, PhD, Chairman of the Board at BostonSight. “The Board would like to thank Gene for his tremendous contributions as President and CEO these last three years. He has helped build an operational and strategic foundation that will allow us to aggressively pursue our objectives in the coming years.”
About BostonSight
BostonSight is an internationally renowned nonprofit eye healthcare organization with a mission to improve the quality of life for patients and their families by transforming the understanding, treatment and care of the ocular surface. For more information, visit www.bostonsight.org.
